TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Radiopharm Theranostics Limited ( (AU:RAD) ).
Radiopharm Theranostics announced its participation in the Deutsche Bank ADR Virtual Investor Conference, where CEO Riccardo Canevari will present the company’s developments. Recent highlights include raising approximately A$35 million in capital and promising preliminary data from several clinical trials, including RAD 101, RAD 202, RAD 204, and RAD 301, indicating strong progress in their oncology radiopharmaceuticals pipeline.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative radiopharmaceutical products for diagnostic and therapeutic applications in oncology. The company is listed on ASX and NASDAQ and has a pipeline of platform technologies including peptides, small molecules, and monoclonal antibodies targeting various solid tumor cancers.
Average Trading Volume: 6,293,854
Technical Sentiment Signal: Sell
Current Market Cap: A$66.74M
See more data about RAD stock on TipRanks’ Stock Analysis page.